The panelists weigh in on the appropriate standards for treating patients with NSCLC.
The panelists weigh in on the appropriate standards for treating patients with NSCLC. These options include radiation, ablation, surgery, and various therapies for the disease.
“The modern surgical techniques have made a major difference. Patients are getting out of the hospital faster, and better shape — fewer complications, fewer morbidities and the consequence of that is if they are candidate for additional treatment after that…they are far better able to tolerate that treatment,” says Dr Langer. He also suggests that surgery must be done right.
“I think there’s a variety of different methods to ablate the tumor ̶ surgery is certainly the foundation of therapy ̶ but particularly for those directing managed care coverage there are other modalities that are very effective in selective settings,” says Dr Peskin.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More